Gilead’s Trodelvy fails to meet main goal in late-stage study

(Reuters) – Gilead Sciences said on Thursday its drug Trodelvy, tested in patients with bladder cancer who previously received chemotherapy, did not meet the main goal of a late-stage study.

(Reporting by Sneha S K; Editing by Alan Barona)